There is considerable evidence that somatostatin is released from nerve terminals throughout the central nervous system in response to presynaptic stimulation, thus suggesting a neuromodulator role for the peptide. We here report the partial characterization of immunoreactive somatostatin released from rat nervous system in vitro (hypothalamus, spinal cord and hypothalamic, cortical, thalamic and striatal synaptosomes). Serial dilutions of released somatostatin immunoreactivity showed parallelism with dilutions of synthetic somatostatin standard. Somatostatin immunoreactivity released from all tissue areas coeluted with synthetic tetradecapeptide on Sephadex G-25 (fine-grade) gel chromatography; more than 85% of this immunoreactivity bound to Sepharose-anti-somatostatin-serum immunoaffinity columns. In addition, immunoreactive material released from hypothalamus, spinal cord and hypothalamic and cortical synaptosomes inhibited somatotropin (growth hormone,
There is considerable evidence that somatostatin is released from nerve terminals throughout the central nervous system in response to presynaptic stimulation, thus suggesting a neuromodulator role for the peptide. We here report the partial characterization of immunoreactive somatostatin released from rat nervous system in vitro (hypothalamus, spinal cord and hypothalamic, cortical, thalamic and striatal synaptosomes). Serial dilutions of released somatostatin immunoreactivity showed parallelism with dilutions of synthetic somatostatin standard. Somatostatin immunoreactivity released from all tissue areas coeluted with synthetic tetradecapeptide on Sephadex G-25 (fine-grade) gel chromatography; more than 85% of this immunoreactivity bound to Sepharose-anti-somatostatin-serum immunoaffinity columns. In addition, immunoreactive material released from hypothalamus, spinal cord and hypothalamic and cortical synaptosomes inhibited somatotropin (growth hormone, 'STH', 'GH') release from perifused anterior pituitary in a dose-related manner, indicating biological similarity to synthetic somatostatin.
Somatostatin has a widespread and uneven distribution throughout mammalian brain, possesses direct depressant effects on central-neuronal function as well as a number of behavioural effects, and is localized in nerve terminals, synaptosomes and secretory granules (Krieger & Martin, 1981) .
The release of immunoreactive somatostatin has been described from a variety of rat central-nervoussystem preparations in vitro, including incubated hypothalami (Berelowitz et al., 1978a) , perifused mediobasal hypothalami (Terry et al., 1980) , incubated median eminence fragments (Negro-Vilar et al., 1978) , neurohypophysis (Patel et al., 1977) , superfused slices of rat hypothalamus and amygdala (Iversen et al., 1978) , synaptosomes isolated from various areas of rat brain (Bennett et al., 1979) , and, in addition, rat spinal cord (Sheppard et al., 1979) .
In all instances the release of somatostatin shares two important characteristics with the neurosecretory process: stimulation of release in response to membrane depolarization and dependence of this process on extracellular Ca2+. There is thus strong evidence that somatostatin may have a neuromodulator role in the nervous system, being released from nerve terminals throughout the brain in Abbreviation used: 125ITyr, [125l1iodotyrosine. Vol. 201 response to presynaptic stimulation, in addition to its probable hypophysiotrophic function in regulating somatotropin (growth hormone, 'STH', 'GH') secretion. Although radioimmunoassays used for the measurement of somatostatin under these conditions are specific, in that no cross-reactivity has been observed with a large number of peptides and hormones, true identity of the measured immunoreactivity with synthetic tetradecapeptide somatostatin still remains to be proven. In the present study we report the partial characterization of immunoreactive somatostatin released from incubated rat hypothalamus (Berelowitz et al., 1978a) , synaptosomes isolated from rat brain (Bennett et al., 1979; Sheppard, 1981) , and incubated rat spinal cord (Sheppard et al., 1979) by means of: (1) comparison of serial dilutions of sample immunoreactivity with the radioimmunoassay doseresponse curve; (2) Sephadex G-25 (fine-grade) gel chromatography; (3) immunoaffinity chromatography; and (4) inhibition of somatotropin secretion from the rat pituitary in vitro. Although it is accepted that final identification of the measured immunoreactive somatostatin depends on amino acid sequencing, the demonstration of identity of immunoreactivity with synthetic tetradecapeptide somatostatin in the four systems described would be 0306-3275/82/020321-08$01.50/1 ©) 1982 The Biochemical Society strong evidence for the released material being biologically active tetradecapeptide somatostatin.
Materials and methods
Rat hypothalami, spinal cord and rat brain synaptosomes were incubated under carefully controlled conditions as previously described in detail (Berelowitz et al., 1978a; Sheppard et al., 1979; Bennett et al., 1979; Berelowitz et al., 1978b) . Medium was frozen and stored at -20°C after the incubation period. Somatostatin was measured by radioimmunoassay as previously detailed (Kronheim et al., 1976) .
Comparison of serial dilutions of sample immunoreactivity with the radioimmunoassay doseresponse curve Measured immunoreactivity in an unknown sample and synthetic standard must be shown to react identically with the antibody (Yalow & Berson, 1971) . This can be done by demonstrating that inhibition curves generated in the immunoassay by somatostatin immunoreactivity are parallel to the inhibition curve produced by synthetic standard. Serial dilutions of medium immunoreactivity obtained from all tissue preparations were prepared in the immunoassay buffer and the inhibition curves generated in the immunoassay compared with those obtained by dilution of somatostatin standards. The results were analysed by linear transformation of the inhibition curves to enable comparison of slopes (Feldman & Rodbard, 1971 
Gel chromatography
Sephadex gels have been used extensively in the purification and characterization of somatostatin (Coy et al., 1973; Yamashiro & Li, 1973; Rivier, 1974) . For the purposes of the present study, Sephadex G-25 (fine grade) was used throughout. The gel was swollen in 1 M-acetic acid at room temperature for 3 h and degassed before pouring 1.6cm x 90cm or 1.6cm x 94cm columns, which were kept at 40C. A constant flow rate of 30ml/h was maintained by means of a peristaltic pump (LKB). Samples (2ml) of medium removed from hypothalamus and spinal cord after 30min of incubation, and of supernatant from synaptosome suspension centrifuged after 30min incubation, were applied to the column. Fractions (5 ml) were eluted with 1 M-acetic acid, freeze-dried and reconstituted in immunoassay buffer before being analysed for somatostatin immunoreactivity. 
Affinity chromatography
To determine whether measured somatostatin immunoreactivity was truly immunoreactive and not the result of non-specific immunoassay interference, CNBr-activated Sepharose was coupled to precipitates of rabbit anti-somatostatin serum and nonimmune rabbit serum. Columns were prepared of both, and the elution patterns of sample and synthetic standard compared. A 40%-satd. (NH4)2SO4 precipitate of somatostatin antiserum was dialysed and coupled to CNBr-activated Sepharose 4B (Pharmacia Fine Chemicals, Uppsala, Sweden), the conjugate was washed and the binding sites that had not reacted were blocked with 1 Methanolamine. Columns (1 cm x 1 cm) were prepared, equilibrated with 0.01 M-phosphate in 0.015 M-NaCl, pH 7.8 (phosphate-buffered saline), and the sample (synthetic tetradecapeptide somatostatin or released immunoreactive material from hypothalamus, spinal cord and hypothalamic and cortical synaptosomes) was recycled for 2 h by using peristaltic pumps (LKB) at a flow rate of 30ml/h. After this time, ten 2 ml fractions were eluted with phosphate-buffered saline to recover non-antibody-bound assayable material; a further ten 2 ml fractions were eluted with 1 M-acetic acid to remove the bound material. Controls consisted of columns containing Sepharose conjugated to nonimmune rabbit serum. Non-specific adsorption to the column was calculated from the amount of material applied and the total eluted with both phosphatebuffered saline and acetic acid. Standard or sample immunoreactivity eluted with phosphate-buffered saline and with acetic acid was expressed as a percentage of total material eluted from the column.
Biological activity of released immunoreactive somatostatin
To determine whether the immunoreactive somatostatin released from rat brain preparations in vitro possessed biological activity, the material was tested in a rat hemipituitary perifusion system. To ensure that biological activity of only immunoreactive somatostatin was being assessed, acetic acid eluates from the above-described Sepharosesomatostatin antiserum affinity columns were freezedried, resuspended in perifusion medium and tested in the hemipituitary system. Anterior pituitary glands were obtained from male Long-Evans rats weighing 200-250g. Rats were decapitated, their brains reflected and removed, and the pituitary rapidly dissected free from the fossa. The posterior pituitary was excised and discarded and the anterior pituitary halved. A chamber to hold the tissue was devised from a 2 ml disposable syringe with inflow via a needle inserted through the rubber piston; the volume of contents was decreased to 0.2 ml during experiments. Two hemipituitaries (from different animals) were placed in the reaction chamber, which was then submerged in a water bath at 370C. Modified Gey and Gey buffer (see below), equilibrated with 02/CO2(19: 1), was pumped through two such chambers (each containing two hemipituitaries) by means of an LKB multiperpex pump for 24h of preincubation and stabilization. The effluent (perfusate) thereafter was collected in 2 ml portions (equivalent to 4 min) on a fraction collector (LKB). Modified Gey and Gey buffer (Carlson et al., 1974) comprised: NaCl, 111 mM; KCI, 3.7 mM; KH2PO4, 0.22mm; NaHCO3, 27mm; MgSO4, 0.28 mM; MgCI2, 1.03 mM; CaCI2, 2.64 mM; Na2HPO4, 0.79 mM; D-glucose, 0.1% (w/v); and bovine serum albumin, 1% (w/v; Miles, fraction V).
Test substances were dissolved in the above medium to give final concentrations in the reaction chamber of: (1) theophylline (Calbiochem), 0.5, 1.5, 2.5, 5.5 and 10.0mM; and (2) synthetic tetradecapeptide somatostatin (Ayerst 24910), 0.05, 0.10, 0.25, 0.50 and 1.OOng/ml. In addition, 1 Macetic acid eluates from coupled Sepharose-somatostatin antiserum columns containing immunoreactive somatostatin released from hypothalamus, hypothalamic and cortical synaptosomes, and spinal cord were freeze-dried, resuspended in perifusion buffer and diluted serially in buffer. These test substances were introduced into the, system via a three-way metal valve and each perifusate fraction was assayed for rat somatotropin with reagents supplied by the National Institute of Arthritis, Metabolism and Digestive Diseases (NIAMDD).
Viability of the hemipituitary preparation was assessed by the Warburg technique in medium comprising: NaCl, 119mM; KCI, 4.7mM; KH2PO4, 1.2 mM; Na2HPO4, 20mM; MgSO4, 1.2mM; and CaCl2, 2.5 mM, equilibrated with 100% 02'
The following perifusion experiments were performed: (1) dose-response effect of theophylline on basal rat somatotropin release; (2) dose-response effect of synthetic somatostatin on 2.5 mmtheophylline-stimulated rat somatotropin release; and (3) effect of serial dilutions of immunoreactive somatostatin on 2.5 mM-theophylline-stimulated rat somatotropin release. The calculation of results was performed as follows.
(1) Basal somatotropin release (B) = mean value for four fractions before stimulus (after 150 min preincubation period). Somatotropin response to stimulus (R) = mean value for four fractions after stimulus.
( consumption over 6h (r = 0.954, P < 0.001), with a consumption rate of 212.9 + 14.5 ,mol of 02/h per g (mean + S.E.M., n = 3).
(2) Theophylline at 0.5-10.0mM caused a dosedependent increase in the release of rat somatotropin (Fig. 7) . For all further experiments a concentration of 2.5 mM-theophylline was chosen, a value closely corresponding to the concentration giving rise to the half-maximal response.
(3) Synthetic somatostatin at 0.05-1.OOng/ml caused a dose-dependent inhibition of 2.5 mM-theophylline-stimulated rat somatotropin release, allowing a dose-response curve to be constructed (Fig. 8) .
(4) Freeze-dried 1 M-acetic acid eluates from anti-somatostatin affinity columns (resuspended in perifusion buffer) inhibited 2.5 mM-theophyllinestimulated rat somatotropin release in all instances. Logit-log transformation of results obtained from studying the inhibitory effect of serial dilutions of released immunoreactive somatostatin allowed comparison with a similarly transformed inhibition curve resulting from dilutions of synthetic somatostatin standard. Serial dilutions of somatostatin immunoreactivity released from all four tissues studied [Theophyllinel (mM) See the text for calculation of logit (inhibitory response). showed parallelism with decreasing amounts of synthetic somatostatin (Figs. 9 and 10 ).
Discussion
Inhibition curves generated in the immunoassay by somatostatin immunoreactivity released from rat hypothalamus, spinal cord and hypothalamic, cortical, thalamic and striatal synaptosomes were Percentage recovery from the columns was calculated from the amount of material applied to the column and the total eluted with both phosphate-buffered saline and 1 M-acetic acid. The amount of synthetic somatostatin standard or sample immunoreactivity (released immunoreactive material from hypothalamus, spinal cord and hypothalamic and cortical synaptosomes) eluted with phosphate-buffered saline and with acetic acid was expressed as a percentage of total material eluted from the column. Results are expressed as means + S.E.M., n = 3. (Maeda & Frohman, 1980; Terry et al., 1980; Richardson et al., 1980) , serial dilutions of medium somatostatin immunoreactivity from incubated or perifused hypothalamic fragments were shown to be parallel in activity to dilutions of synthetic somatostatin standards, confirming the immunological similarity of somatostatin released from rat hypothalamus in vitro to the synthetic tetradecapeptide. We have now confirmed the release of immunologically reactive somatostatin from extrahypothalamic areas.
The chromatographic characteristics of centralnervous-system immunoreactive somatostatin have been studied extensively. There is considerable evidence that hypothalamic and extrahypothalamic tissues contain somatostatin-like substances having molecular weights greater than that of the tetradecapeptide. A fairly recent report has described the existence of three molecular-weight species of somatostatin-like immunoreactivity separated from acetic acid extracts of rat hypothalamus (Spiess & Vol. 201 Vale, 1980); Bohlen et al. (1980) have isolated a biologically active somatostatin containing 28 amino acid residues from ovine hypothalami, as well as a shorter, 25-amino-acid, peptide; and Zingg & Patel (1979) have reported the existence of two highmolecular-weight forms of immunoreactive somatostatin in rat median eminence and neurohypophysis in addition to tetradecapeptide somatostatin. Rorstadt et al. (1979) have shown that immunoaffinity-purified immunoreactive somatostatin from four rat brain areas (median eminence, anterior hypothalamnic-preoptic area, amygdala and parietal cortex) eluted as four peaks on Sephadex G-25 (fine grade) gel chromatography. In addition, each peak possessed biological activity by virtue of its ability to inhibit somatotropin release from cultured rat anterior-pituitary cells. There seems little doubt, therefore, that a number of different molecularweight forms of somatostatin-like immunoreactivity exist which have similar immunological and biological activities but different physicochemical properties.
The chromatographic characteristics of the released material are less well-defined. The highmolecular-weight forms of somatostatin-like immunoreactivity described by Zingg & Patel (1979) were released into the medium from incubated rat median eminence and neurohypophysis in vitro. Richardson et aL (1980) demonstrated, by Sephadex G-25 chromatographic studies, that although the bulk of somatostatin immunoreactivity released from incubated hypothalamic fragments co-eluted with synthetic tetradecapeptide somatostatin, two further peaks of immunoreactivity were present which eluted in advance of synthetic somatostatin. High-pressure liquid chromatography confirmed that the third peak co-eluted with synthetic tetradecapeptide. By contrast, in the present studies and in those of Maeda & Frohman (1980) , all the recovered immunoreactive somatostatin co-eluted with the synthetic tetradecapeptide. It would appear, therefore, that central-nervous-system extracts contain multiple molecular-weight species, whereas released material is predominantly a single species with the former perhaps representing peptide at various stages of processing from precursor. Inability of the antiserum used to recognize highmolecular-weight forms is another possibility. The antiserum used in our studies shows good crossreaction with des-Alal-Gly2-somatostatin, [Tyrll- somatostatin and cyclic-(4-13)-somatostatin, but no cross-reactivity with biologically inactive D-Phe6-, D-Phe7-, Phe8-or Pro8-substituted somatostatin (Berelowitz et al., 1978c) , suggesting a locus of cross-reactivity away from the N-terminus and related to amino acids in positions 6-8, regarded as biologically important for somatotropin inhibition.
The biological activity of the released immunoreactive somatostatin has been assessed by the ability of the material to inhibit theophyllinestimulated somatotropin release from the anterior pituitary. A number of advantages have been claimed for perifusion of anterior pituitaries, and these include: (1) the ability to apply a sequence of tests to a single gland so that each gland acts as its own control; (2) the continuous turnover of medium, which thus minimizes the effects of accumulation of secretory or metabolic products and decreases the breakdown of substances secreted by the gland or administered to evoke a response; and (3) the demonstration that perifused rat pituitaries remain responsive to stimuli for at least 6h, accompanied by linear somatotropin synthesis for 8h (Dowd et al., 1975; Stachura & Frohman, 1974) . To ensure that the biological activity of only immunoreactive somatostatin was being assessed, acetic acid eluates from Sepharose-somatostatinantiserum affinity columns were freeze-dried, resuspended in perifusion medium and tested in the system. The demonstration that the immunoreactive material from hypothalamus, spinal cord and hypothalamic and cortical synaptosomes inhibited somatotropin release in a parallel dose-related manner indicates the biological similarity to synthetic somatostatin, and demonstrates that even though the peptide may have a neuromodulator function in the extrahypothalamic nervous system, it nevertheless has the biological potential to inhibit somatotropin secretion. It should once again be emphasized, however, that despite immunological and biological similarity between the material released from these hypothalamic and extrahypothalamic areas and synthetic tetradecapeptide somatostatin, confirmation of identity awaits purification and sequencing of the polypeptide.
